Ocugen, Inc. (OCGN)Healthcare | Biotechnology | Malvern, United States | NasdaqCM
1.41 USD
-0.06
(-4.082%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.42 +0.01 (0.709%) ⇧ (July 13, 2026, 7:49 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:14 a.m. EDT
The investment case here is fundamentally broken. The company is burning through cash with negative operating and free cash flows, resulting in a massive debt-to-equity ratio that suggests severe financial distress. The balance sheet is fragile, with liabilities significantly outweighing equity, and the business has failed to generate sustainable revenue growth over the last decade, eroding shareholder value by nearly 99% since 2016. While analysts have set lofty price targets, these are likely theoretical valuations based on potential future success rather than current reality, as the stock trades at a premium to sales despite having no earnings. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further drops. Without a confirmed, transformative clinical trial result or a drastic reduction in debt, the risk of permanent capital loss far outweighs any speculative upside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.076932 |
| AutoARIMA | 0.088561 |
| AutoETS | 0.088576 |
| MSTL | 0.123222 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 5.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.141 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 573.575 |
| Revenue per Share | 0.014 |
| Market Cap | 477,315,808 |
| Forward P/E | -6.00 |
| Beta | 2.18 |
| Website | https://www.ocugen.com |
As of July 11, 2026, 5:14 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes at 0.5 and 1.0) compared to negligible call volume. While there is some speculative call activity at higher strikes (3.0-3.5) for later expirations, the overwhelming capital allocation is in put writing and buying, suggesting a consensus view of continued volatility and potential further decline rather than a near-term catalyst.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.32432437 |
| Address1 | 11 Great Valley Parkway |
| All Time High | 778.2 |
| All Time Low | 0.17 |
| Ask | 1.62 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 12,226,700 |
| Average Daily Volume3 Month | 7,898,809 |
| Average Volume | 7,898,809 |
| Average Volume10Days | 12,226,700 |
| Beta | 2.181 |
| Bid | 1.23 |
| Bid Size | 1 |
| Book Value | 0.017 |
| City | Malvern |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.41 |
| Current Ratio | 1.862 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.465 |
| Day Low | 1.4 |
| Debt To Equity | 573.575 |
| Display Name | Ocugen |
| Dividend Date | 1,569,801,600 |
| Earnings Call Timestamp End | 1,777,984,200 |
| Earnings Call Timestamp Start | 1,777,984,200 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,414,600 |
| Earnings Timestamp Start | 1,785,414,600 |
| Ebitda | -63,870,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.496 |
| Enterprise To Revenue | 107.224 |
| Enterprise Value | 478,756,832 |
| Eps Current Year | -0.22333 |
| Eps Forward | -0.235 |
| Eps Trailing Twelve Months | -0.24 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4125 |
| Fifty Day Average Change | -0.0025000572 |
| Fifty Day Average Change Percent | -0.001769952 |
| Fifty Two Week Change Percent | 32.432438 |
| Fifty Two Week High | 2.725 |
| Fifty Two Week High Change | -1.3149999 |
| Fifty Two Week High Change Percent | -0.4825688 |
| Fifty Two Week Low | 0.931 |
| Fifty Two Week Low Change | 0.47899997 |
| Fifty Two Week Low Change Percent | 0.5145005 |
| Fifty Two Week Range | 0.931 - 2.725 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,417,617,000,000 |
| Float Shares | 316,842,916 |
| Forward Eps | -0.235 |
| Forward P E | -6.0 |
| Free Cashflow | -33,665,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 116 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -37,011,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01683 |
| Held Percent Institutions | 0.34572 |
| Implied Shares Outstanding | 338,521,856 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,569,801,600 |
| Last Split Factor | 1:60 |
| Long Business Summary | Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. |
| Long Name | Ocugen, Inc. |
| Market | us_market |
| Market Cap | 477,315,808 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_303874231 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -71,673,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 497,627,128 |
| Number Of Analyst Opinions | 7 |
| Open | 1.44 |
| Operating Cashflow | -59,401,000 |
| Operating Margins | -11.636661 |
| Payout Ratio | 0.0 |
| Phone | 484 328 4701 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.7092192 |
| Post Market Price | 1.42 |
| Post Market Time | 1,783,986,598 |
| Previous Close | 1.47 |
| Price Eps Current Year | -6.3135266 |
| Price Hint | 4 |
| Price To Book | 82.94117 |
| Price To Sales Trailing12 Months | 106.901634 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.538 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0600001 |
| Regular Market Change Percent | -4.08164 |
| Regular Market Day High | 1.465 |
| Regular Market Day Low | 1.4 |
| Regular Market Day Range | 1.4 - 1.465 |
| Regular Market Open | 1.44 |
| Regular Market Previous Close | 1.47 |
| Regular Market Price | 1.41 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 5,482,056 |
| Return On Assets | -0.68237996 |
| Return On Equity | -6.60003 |
| Revenue Growth | 0.035 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 338,521,856 |
| Shares Percent Shares Out | 0.3114 |
| Shares Short | 105,430,735 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 83,020,405 |
| Short Name | Ocugen, Inc. |
| Short Percent Of Float | 0.31309998 |
| Short Ratio | 10.98 |
| Source Interval | 15 |
| State | PA |
| Symbol | OCGN |
| Target High Price | 22.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 11.42857 |
| Target Median Price | 10.0 |
| Total Cash | 31,855,000 |
| Total Cash Per Share | 0.094 |
| Total Debt | 33,296,000 |
| Total Revenue | 4,465,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.553075 |
| Two Hundred Day Average Change | -0.14307499 |
| Two Hundred Day Average Change Percent | -0.09212369 |
| Type Disp | Equity |
| Volume | 5,482,056 |
| Website | https://www.ocugen.com |
| Zip | 19,355 |